PCSK9 and coronary artery disorder: Among the African American patients (n = 3363) involved in the study, 2.6% carried a heterozygous non-sense PCSK9 variant (Y142X or C679X), which led to a 28% reduction in circulating LDLc and was associated with an 88% reduction in coronary heart disease (CHD) [4].